Latexin exhibits tumor suppressor potential in hepatocellular carcinoma

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1364-1372

  Ni, Qing Feng ^a   Tian, Yuan ^a   Kong, Liang Liang ^a   Lu, Ye Ting ^a   Ding, Wen Zhou ^a   Kong, Lian Bao ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Hepatocellular carcinoma; Latexin; Proliferation

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN E; LATEXIN; MESSENGER RNA; SHORT HAIRPIN RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; COLONY FORMING CELL; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LATEXIN GENE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TUMOR GENE; TUMOR GROWTH;

ANIMALS; ANTIGENS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; TUMOR BURDEN;

EID: 84896696405     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.2966     Document Type: Article

References (35)

1. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003. (Pubitemid 37518510)
2. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nature Rev Cancer 6: 674-687, 2006. (Pubitemid 44286000)
3. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
4. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10: 1111-1118, 2009.
5. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
6. Coleman WB: Mechanism of human hepatocarcinogenesis. Curr Mol Med 3: 573-588, 2003.
7. Caldwell S and Park SH: The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 44 (Suppl 19): 96-101, 2009.
8. Bosch FX, Ribes J and Borràs J: Epidemiology of primary liver cancer. Semin Liver Dis 19: 271-285, 1999. (Pubitemid 29488770)
9. Tung-Ping Poon R, Fan ST and Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10-24, 2000.
10. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA and Giulini SM: Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 243: 229-235, 2006. (Pubitemid 43185442)
11. Hatanaka Y, Uratani Y, Takiguchi-Hayashi K, Omori A, Sato K, Miyamoto M and Arimatsu Y: Intracortical regionality represented by specific transcription for a novel protein, latexin. Eur J Neurosci 6: 973-982, 1994. (Pubitemid 24185321)
12. Liu Q, Yu L, Gao J, Fu Q, Zhang J, Zhang P, Chen J and Zhao S: Cloning, tissue expression pattern and genomic organization of latexin, a human homologue of rat carboxypeptidase A inhibitor. Mol Biol Rep 27: 241-246, 2000. (Pubitemid 32608414)
13. Aagaard A, Listwan P, Cowieson N, Huber T, Ravasi T, Wells CA, Flanagan JU, Kellie S, Hume DA, Kobe B and Martin JL: An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1. Structure 13: 309-317, 2005. (Pubitemid 40247706)
14. Pallarès I, Bonet R, García-Castellanos R, Ventura S, Avilés FX, Vendrell J and Gomis-Rüth FX: Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. Proc Natl Acad Sci USA 102: 3978-3983, 2005.
15. Jing C, El-Ghany MA, Beesley C, Foster CS, Rudland PS, Smith P and Ke Y: Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst 94: 482-490, 2002. (Pubitemid 34411286)
16. Liang Y, Jansen M, Aronow B, Geiger H and Van Zant G: The quantitative trait gene latexin influences the size of the hematopoietic stem cell population in mice. Nat Genet 39: 178-188, 2007. (Pubitemid 46184348)
17. Mitsunaga K, Kikuchi J, Wada T and Furukawa Y: Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells. J Cell Physiol 227: 1138-1147, 2012.
18. Van Zant G and Liang Y: Natural genetic diversity as a means to uncover stem cell regulatory pathways. Ann NY Acad Sci 1176: 170-177, 2009.
19. Ke Y, Xu GW, Hagiwara K, Zhang JM, Ning T, Wang B, Su XL, Feng LY, Lu GR, Lu YY and Harris CC: Isolation and sequencing of the target genes induced by chemical carcinogen. Science in China (Series C) 26: 85-91, 1996.
20. Elledge SJ: Cell cycle checkpoints: preventing an identity crisis. Science 274: 1664-1672, 1996.
21. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
22. Li Y, Basang Z, Ding H, et al: Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential. BMC Cancer 11: 111-121, 2011.
23. Greaves M and Maley CC: Clonal evolution in cancer. Nature 481: 306-313, 2012.
24. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225, 1997.
25. Eastham JA, Hall SJ, Sehgal I, et al: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55: 5151-5155, 1995.
26. Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14: 2283-2289, 1997.
27. WAF1/CIP1 on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 13: 1395-1403, 1996.
28. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371: 257-261, 1994.
29. Guan KL, Jenkins CW, Li Y, et al: Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8: 2939-2952, 1994.
30. Hirai H, Roussel MF, Kato JY, et al: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15: 2672-2681, 1995.
31. Chan FK, Zhang J, Cheng L, et al: Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 15: 2682-2688, 1995.
32. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999. (Pubitemid 29297917)
33. Kiviharju-af Hällström TM, Jäämaa S, Mönkkönen M, et al: Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci USA 104: 7211-7216, 2007.
34. Yoshida T, Tanaka S, Mogi A, et al: The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 15: 252-256, 2004. (Pubitemid 38262624)
35. Quelle DE, Ashmun RA, Shurtleff SA, et al: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7: 1559-1571, 1993. (Pubitemid 23234349)